CD93 belongs to the group XIV C-type lectin like domain (CTLD) and is closely related to thrombomodulin (CD141). Although CD93 is known to be involved in the regulation of cell adhesion and phagocytosis, its role in innate immunity remains to be fully investigated. Critically, published data about CD141 suggest that CD93 CTLD could be involved in the control of inflammation. In order to address further functional and structural analyses, we expressed human CD93 CTLD with several disulfide bonds in an E. coli expression system. As the E. coli cytoplasm is a reducing compartment, production of disulfide-bond proteins remains a challenge. Hence, we decided to over express CD93 CTLD in commercially available strains of E. coli and co-expressed a sulfhydryl oxidase (Erv1p) and a disulfide isomerase (DsbC). This strategy led to high yield expression of a native form of CD93 CTLD. NMR studies revealed that Ca was not able to bind to CD93 CTLD. We also showed that the recombinant protein could alter LPS pro-inflammatory activity on THP1. This work provides new tool for further functional and structural studies to decipher the functions associated to the CTLD of CD93. This approach may also be used for others members of the group XIV C-type lectin like domain (CD141, CD248 and CLec14A).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jim.2016.10.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Group XIV C-type lectins: emerging targets in tumor angiogenesis.
Angiogenesis
May 2024
Department of Surgery, University of Colorado Anschutz Medical Campus, 12800 E 19th Avenue, RC1-North, P18-8116, Aurora, CO, 80045, USA.
C-type lectins, distinguished by a C-type lectin binding domain (CTLD), are an evolutionarily conserved superfamily of glycoproteins that are implicated in a broad range of physiologic processes. The group XIV subfamily of CTLDs are comprised of CD93, CD248/endosialin, CLEC14a, and thrombomodulin/CD141, and have important roles in creating and maintaining blood vessels, organizing extracellular matrix, and balancing pro- and anti-coagulative processes. As such, dysregulation in the expression and downstream signaling pathways of these proteins often lead to clinically relevant pathology.
View Article and Find Full Text PDFBioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93.
Front Bioinform
June 2022
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Article Synopsis
- CD93 is a transmembrane glycoprotein that could be targeted to hinder tumor blood vessel growth, with Multimerin-2 (MMRN2) identified as its binding partner.
- This study explores how mutations in the C-type lectin-like domain (CTLD) of CD93 affect its interaction with MMRN2, using experimental data and computational modeling.
- The findings provide valuable insights for drug development aimed at interrupting the CD93-MMRN2 interaction, which could be beneficial in cancer treatment.
CD93 is a cell surface lectin receptor involved in the control of the inflammatory response stimulated by exogenous DNA.
Immunology
October 2019
GRI, Groupe de recherche en immunopathologie, EA4517, Université de la Réunion, Saint-Denis, France.
Bacterial DNA contains CpG oligonucleotide (ODN) motifs to trigger innate immune responses through the endosomal receptor Toll-like receptor 9 (TLR9). One of the cell surface receptors to capture and deliver microbial DNA to intracellular TLR9 is the C-type lectin molecule DEC-205 through its N-terminal C-type lectin-like domain (CTLD). CD93 is a cell surface protein and member of the lectin group XIV with a CTLD.
View Article and Find Full Text PDFC-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
FEBS J
September 2019
Institutes of Cardiovascular Sciences and Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, UK.
The C-type lectin domain (CTLD) group 14 family of transmembrane glycoproteins consist of thrombomodulin, CD93, CLEC14A and CD248 (endosialin or tumour endothelial marker-1). These cell surface proteins exhibit similar ectodomain architecture and yet mediate a diverse range of cellular functions, including but not restricted to angiogenesis, inflammation and cell adhesion. Thrombomodulin, CD93 and CLEC14A can be expressed by endothelial cells, whereas CD248 is expressed by vasculature associated pericytes, activated fibroblasts and tumour cells among other cell types.
View Article and Find Full Text PDFSoluble expression of disulfide-bonded C-type lectin like domain of human CD93 in the cytoplasm of Escherichia coli.
J Immunol Methods
December 2016
GRI, EA4517, Université de la Réunion, Saint-Denis F-97400, France; CALIXAR, 60 Avenue Rockefeller, 69008 Lyon, France.
CD93 belongs to the group XIV C-type lectin like domain (CTLD) and is closely related to thrombomodulin (CD141). Although CD93 is known to be involved in the regulation of cell adhesion and phagocytosis, its role in innate immunity remains to be fully investigated. Critically, published data about CD141 suggest that CD93 CTLD could be involved in the control of inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!